{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=WHO+Grade+II+Glioma&page=4", "query": { "condition": "WHO Grade II Glioma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 108, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=WHO+Grade+II+Glioma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=WHO+Grade+II+Glioma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T18:46:04.721Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02034110", "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 206, "start_date": "2014-03-12", "completion_date": "2021-12-10", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02034110" }, { "nct_id": "NCT01076530", "title": "Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Embryonal Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Extra-adrenal Paraganglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Spinal Cord Neoplasm", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 27, "start_date": "2010-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 7, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076530" }, { "nct_id": "NCT05859334", "title": "Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioma", "Recurrent WHO Grade 2 Glioma", "Recurrent WHO Grade 3 Glioma", "Recurrent WHO Grade 4 Glioma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Optical Coherence Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-01-04", "completion_date": "2026-10-23", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 27, "location_summary": "Aurora, Colorado • Coral Gables, Florida • Deerfield Beach, Florida + 19 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Shiloh", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05859334" }, { "nct_id": "NCT04320888", "title": "Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoma", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent WHO Grade 2 Glioma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Histiocytic and Dendritic Cell Neoplasm", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoma", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory WHO Grade 2 Glioma", "Wilms Tumor" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1, "start_date": "2021-05-03", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 172, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04320888" }, { "nct_id": "NCT00503724", "title": "Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neuroblastoma" ], "interventions": [ { "name": "enzastaurin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 32, "start_date": "2007-06", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2012-03-06", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 8, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00503724" }, { "nct_id": "NCT00020579", "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 3, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020579" }, { "nct_id": "NCT00110032", "title": "Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Central Nervous System Germ Cell Tumor", "Adult Choroid Plexus Tumor", "Adult Craniopharyngioma", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Ependymoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Grade I Meningioma", "Adult Grade II Meningioma", "Adult Grade III Meningioma", "Adult Medulloblastoma", "Adult Meningeal Hemangiopericytoma", "Adult Mixed Glioma", "Adult Myxopapillary Ependymoma", "Adult Oligodendroglioma", "Adult Pilocytic Astrocytoma", "Adult Pineoblastoma", "Adult Pineocytoma", "Adult Subependymoma", "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)", "Meningeal Melanocytoma" ], "interventions": [ { "name": "EF5", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "fluorine F 18 EF5", "type": "RADIATION" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2005-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110032" }, { "nct_id": "NCT00020150", "title": "Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "O6-benzylguanine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": null, "start_date": "2000-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020150" }, { "nct_id": "NCT03434262", "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Ganglioglioma", "Anaplastic Meningioma", "Anaplastic Oligodendroglioma", "Pleomorphic Xanthoastrocytoma, Anaplastic", "Atypical Teratoid/Rhabdoid Tumor", "Brain Cancer", "Brain Tumor", "Central Nervous System Neoplasms", "Choroid Plexus Carcinoma", "CNS Embryonal Tumor With Rhabdoid Features", "Ganglioneuroblastoma of Central Nervous System", "CNS Tumor", "Embryonal Tumor of CNS", "Ependymoma", "Glioblastoma", "Glioma", "Glioma, Malignant", "Medulloblastoma", "Medulloblastoma; Unspecified Site", "Medulloepithelioma", "Neuroepithelial Tumor", "Neoplasms", "Neoplasms, Neuroepithelial", "Papillary Tumor of the Pineal Region (High-grade Only)", "Pediatric Brain Tumor", "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)", "Pineoblastoma", "Primitive Neuroectodermal Tumor", "Recurrent Medulloblastoma", "Refractory Brain Tumor", "Neuroblastoma. CNS", "Glioblastoma, IDH-mutant", "Glioblastoma, IDH-wildtype", "Medulloblastoma, Group 3", "Medulloblastoma, Group 4", "Glioma, High Grade", "Neuroepithelial Tumor, High Grade", "Medulloblastoma, SHH-activated and TP53 Mutant", "Medulloblastoma, SHH-activated and TP53 Wildtype", "Medulloblastoma, Chromosome 9q Loss", "Medulloblastoma, Non-WNT Non-SHH, NOS", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, PTCH1 Mutation", "Medulloblastoma, WNT-activated", "Ependymoma, Recurrent", "Glioma, Recurrent High Grade", "Glioma, Recurrent Malignant", "Embryonal Tumor, NOS", "Glioma, Diffuse Midline, H3K27M-mutant", "Embryonal Tumor With Multilayered Rosettes (ETMR)", "Ependymoma, NOS, WHO Grade III", "Ependymoma, NOS, WHO Grade II", "Medulloblastoma, G3/G4", "Ependymoma, RELA Fusion Positive" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "sonidegib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 68, "start_date": "2018-03-05", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434262" }, { "nct_id": "NCT02924038", "title": "A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Malignant Glioma", "Astrocytoma, Grade II", "Oligodendroglioma", "Glioma, Astrocytic", "Oligoastrocytoma, Mixed" ], "interventions": [ { "name": "IMA950", "type": "BIOLOGICAL" }, { "name": "poly-ICLC", "type": "BIOLOGICAL" }, { "name": "Varlilumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nicholas Butowski", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-04-03", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-10-04T18:46:04.721Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924038" } ] }